Literature DB >> 28357106

Persistent arthralgia, vomiting and hypercalcemia as the initial manifestations of hyperthyroidism: A case report.

Jingfang Liu1, Xulei Tang1, Jianguo Cheng1, Xiaomei Yang1, Yan Wang1.   

Abstract

A 53-year-old woman presented with persistent edema and pain of the metacarpophalangeal and proximal interphalangeal joints and the wrist, knee and ankle joints, with more recent intermittent nausea and vomiting. Treatment for rheumatoid arthritis and osteoarthritis was ineffective. No clinical manifestations typical of hyperthyroidism were observed. The results of the thyroid function tests were as follows: Thyroid-stimulating hormone, 0.003 µIU/ml; triiodothyronine (T3), 4.44 ng/ml;, thyroxine (T4) >30 µg/dl; free T3, 14.03 pg/ml; and free T4, 8.84 ng/dl. The laboratory tests revealed an elevated serum calcium level (2.96 mmol/l); moderate hypophosphatemia (0.84 mmol/l); significantly reduced serum intact parathyroid hormone (4.8 pg/ml); normal 25-hydroxy vitamin D (52.13 nmol/l) and bone-specific alkaline phosphatase (22.1 ng/ml); and elevated osteocalcin (128.8 ng/ml). X-ray and quantitative ultrasound examinations revealed extensive osteoporosis of the hands, skull, knees and pelvis, with a bone mineral density of 0.254 g/cm2 (T-score, -3.2). Anti-thyroid therapy (methimazole, 30 mg/day; salmon calcitonin, 50 IU/day; and alendronate, 70 mg/week) was initiated. After 2 weeks, the serum calcium and phosphate levels were normalized (2.44 and 1.19 mmol/l, respectively) and calcitonin was discontinued. After 3 months, the patient had no nausea, vomiting or joint pain, and her appetite was normal, with a weight gain of ~10 kg. Euthyroidism was achieved and the serum calcium and phosphate levels were normalized (2.31 and 1.12 mmol/l, respectively) and maintained for 6 months, by which time the osteocalcin level had diminished (80.40 ng/ml). This rare case of arthralgia, hypercalcemia and extensive osteoporosis as the first manifestations of hyperthyroidism suggests that, even without typical symptoms, hyperthyroidism should be considered in the differential diagnosis of patients with persistent arthralgia.

Entities:  

Keywords:  arthralgia; hypercalcemia; hyperthyroidism; osteoporosis

Year:  2017        PMID: 28357106      PMCID: PMC5351708          DOI: 10.3892/mco.2017.1127

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  9 in total

Review 1.  Effects of thyroid hormones on bone and mineral metabolism.

Authors:  L Mosekilde; E F Eriksen; P Charles
Journal:  Endocrinol Metab Clin North Am       Date:  1990-03       Impact factor: 4.741

2.  Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis.

Authors:  S Nagasaka; H Sugimoto; T Nakamura; I Kusaka; G Fujisawa; N Sakuma; Y Tsuboi; S Fukuda; K Honda; K Okada; S Ishikawa; T Saito
Journal:  Clin Endocrinol (Oxf)       Date:  1997-08       Impact factor: 3.478

3.  Hypercalcemia of thyrotoxicosis.

Authors:  J D Baxter; P K Bondy
Journal:  Ann Intern Med       Date:  1966-09       Impact factor: 25.391

4.  Hyperthyroidism manifested as hypercalcemia.

Authors:  Z Alikhan; A Singh
Journal:  South Med J       Date:  1996-10       Impact factor: 0.954

5.  Radioimmunoassay for the middle region of human parathyroid hormone: studies with a radioiodinated synthetic peptide.

Authors:  S J Marx; M E Sharp; A Krudy; M Rosenblatt; L E Mallette
Journal:  J Clin Endocrinol Metab       Date:  1981-07       Impact factor: 5.958

6.  Bone remodelling markers and serum cytokines in patients with hyperthyroidism.

Authors:  Aysen Akalin; Omer Colak; Ozkan Alatas; Belgin Efe
Journal:  Clin Endocrinol (Oxf)       Date:  2002-07       Impact factor: 3.478

7.  Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis.

Authors:  Ayesha A Iqbal; Elizabeth H Burgess; Daniel L Gallina; Mark S Nanes; Curtiss B Cook
Journal:  Endocr Pract       Date:  2003 Nov-Dec       Impact factor: 3.443

8.  Hypercalcemia in hyperthyroidism. Role of age and goiter type.

Authors:  Z S Szabó; F Ritzl
Journal:  Klin Wochenschr       Date:  1981-03-16

Review 9.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

  9 in total
  2 in total

1.  A retrospective analysis of 1,231 patients with anemia after surgical treatment of hyperthyroidism.

Authors:  Ruisha Tu; Hongfeng Shen; Qicong Zhu; Gaocai Mao; Xiaojiang Xu; Shuyong Yu
Journal:  Exp Ther Med       Date:  2018-09-14       Impact factor: 2.447

2.  Toxic thyroid adenoma with hypercalcemia mimicking an intra-thyroidal parathyroid adenoma.

Authors:  Venkata Subramanian Krishnaraju; Ritesh Upadhyay; Ashwani Sood; Anish Bhattacharya; Bhagwant Rai Mittal
Journal:  Asia Ocean J Nucl Med Biol       Date:  2022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.